Strongbridge Biopharma PLC (SBBP) Rating Lowered to Sell at Zacks Investment Research
Strongbridge Biopharma PLC (NASDAQ:SBBP) was downgraded by Zacks Investment Research from a “hold” rating to a “sell” rating in a report released on Thursday.
According to Zacks, “Strongbridge Biopharma PLC is a biopharmaceutical company which develops, acquires and commercializes product candidates that target rare diseases. Its product candidate consists of COR-003, is a cortisol inhibitor, for the treatment of endogenous Cushing’s syndrome, COR-004 and COR-005 to treat acromegaly, BP-2001, the treatment of diabetes which are in different clinical trial. Strongbridge Biopharma PLC is based in Trevose, Pennsylvania. “
Several other research firms also recently issued reports on SBBP. Oppenheimer Holdings, Inc. began coverage on Strongbridge Biopharma PLC in a research note on Thursday, August 10th. They set an “outperform” rating and a $12.00 price target for the company. ValuEngine raised Strongbridge Biopharma PLC from a “sell” rating to a “hold” rating in a research note on Tuesday, June 27th. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and three have assigned a buy rating to the stock. The stock has a consensus rating of “Hold” and a consensus price target of $11.94.
Shares of Strongbridge Biopharma PLC (NASDAQ SBBP) opened at 7.30 on Thursday. The stock’s 50 day moving average is $6.81 and its 200-day moving average is $5.43. The stock’s market cap is $257.95 million. Strongbridge Biopharma PLC has a 12-month low of $2.00 and a 12-month high of $8.85.
Strongbridge Biopharma PLC (NASDAQ:SBBP) last released its quarterly earnings results on Monday, August 7th. The biotechnology company reported ($0.34) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.34). The firm had revenue of $1.53 million for the quarter, compared to analyst estimates of $0.84 million. Equities analysts anticipate that Strongbridge Biopharma PLC will post ($2.48) EPS for the current fiscal year.
ILLEGAL ACTIVITY NOTICE: This report was first posted by The Cerbat Gem and is the property of of The Cerbat Gem. If you are accessing this report on another publication, it was stolen and reposted in violation of U.S. & international copyright laws. The correct version of this report can be read at https://www.thecerbatgem.com/2017/09/28/strongbridge-biopharma-plc-sbbp-rating-lowered-to-sell-at-zacks-investment-research.html.
A number of hedge funds have recently made changes to their positions in SBBP. Northern Trust Corp acquired a new position in Strongbridge Biopharma PLC in the 2nd quarter valued at about $1,462,000. Broadfin Capital LLC raised its stake in Strongbridge Biopharma PLC by 3.0% in the 1st quarter. Broadfin Capital LLC now owns 2,981,706 shares of the biotechnology company’s stock valued at $14,163,000 after purchasing an additional 87,125 shares during the last quarter. Nexthera Capital LP acquired a new position in Strongbridge Biopharma PLC in the 2nd quarter valued at about $477,000. Vanguard Group Inc. acquired a new position in Strongbridge Biopharma PLC in the 2nd quarter valued at about $474,000. Finally, TIAA CREF Investment Management LLC acquired a new position in Strongbridge Biopharma PLC in the 2nd quarter valued at about $449,000. 63.65% of the stock is owned by hedge funds and other institutional investors.
Strongbridge Biopharma PLC Company Profile
Strongbridge Biopharma plc is a global commercial-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies for a range of diseases. The Company’s commercial product, KEVEYIS (dichlorphenamide), is indicated for the treatment of hyperkalemic, hypokalemic and related variants of primary periodic paralysis.
Receive News & Stock Ratings for Strongbridge Biopharma PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Strongbridge Biopharma PLC and related stocks with our FREE daily email newsletter.